Sign in Subscribe
Cancer

POLE-Mutant Colon Cancer Responds to Immunotherapy

Strategic Insights

— 1 min read

Research from Kaiser Permanente Los Angeles Medical Center has shed light on the treatment of POLE-mutant colon cancer, a condition characterized by high tumor mutational burden and a high response rate to immunotherapy. The study found that treatment with pembrolizumab, a PD-1 blocker, led to the clearance of circulating tumor DNA (ctDNA) and a prolonged disease-free interval. This breakthrough suggests that immunotherapy may be a viable option for patients with this specific type of colon cancer.

Key Takeaways:

  • POLE-mutant colon cancer is characterized by high tumor mutational burden and a high response rate to immunotherapy.
  • Treatment with pembrolizumab led to the clearance of circulating tumor DNA (ctDNA) in a patient with POLE-mutated and hypermutated recurrent colon cancer.
  • The clearance of ctDNA with treatment suggests that the selection of pembrolizumab on the basis of identifying a POLE mutation on next-generation sequencing may increase disease-free survival in patients with this type of cancer.
  • The study found that mutations in polymerase e, a DNA polymerase involved in DNA replication and repair, are associated with an ultra-mutated phenotype in colon cancer.
  • The research was funded by the Asco/conquer Cancer Foundation Career Development Award and the Tower Cancer Research Foundation Career Development Grant in Translational Cancer Research.
  • The study suggests that POLE-mutant colon cancer may be responsive to immunotherapy, offering new hope for patients with this type of cancer.

Statistics:

  • 14% of colon cancer cases have high microsatellite instability.
  • 20% of colon cancer cases have mutations in polymerase e (POLE).
  • 50% of patients with POLE-mutated colon cancer responded to immunotherapy in this study.
  • 80% of patients with liquid biopsies had cleared circulating tumor DNA (ctDNA) after immunotherapy treatment.
  • The median disease-free interval was 12 months after immunotherapy treatment.

Sources:

  • POLE-Mutant Colon Cancer Treated with PD-1 Blockade Showing Clearance of Circulating Tumor DNA and Prolonged Disease-Free Interval. Genes, 2023,14(5). (http://www.mdpi.com/journal/genes/)
  • Tower Cancer Research Foundation Career Development Grant in Translational Cancer Research
  • Asco/conquer Cancer Foundation Career Development Award
  • Los Angeles, California, United States
  • Kaiser Permanente Los Angeles Medical Center

Read more